Diagnostics startup GRIP Molecular is developing an at-home test for Covid-19 and other respiratory infections. The technology builds on advances from several fields, including the discovery of graphene, a material that offers biocompatibility and conductivity.
A panel of three experts at MedCity INVEST Twin Cities chatted about digital health technologies and what's standing in the way of adoption across the board.
During the keynote at MedCity INVEST Twin Cities, Zipnosis cofounder and CEO Jon Pearce discussed how the three amigos of healthcare — the patient, the provider and the payer — are key to digital health adoption.
Since HealthEast Care System in St. Paul, Minnesota, became the first health system in the state to go live with EPCS two years ago, clinicians have saved an aggregate of about 500 hours per month in time spent writing prescriptions for controlled drugs, CHIME attendees heard Wednesday.
The move advances two growing trends: Minnesota’s “big health” players investing in startups and nontraditional providers offering the perhaps the most traditional of healthcare services that has been abandoned by mainstream providers: the house call.
There might be enough room for everyone in the space, but a little competition should be expected.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Medibio is looking to diagnose mental health disorders by examining how heart activity fluctuates with the help of Medtronic.
Additional investors means additional, significant progress for St. Paul, Minnesota-based diagnostics company Ativa Medical.
3M said Thursday that it is "exploring strategic alternatives" for its health information systems division.
Rotation Medical has developed a new way to treat rotator cuff injuries that addresses both the pain and degenerative nature of this problem. The treatment includes a proprietary, reconstituted collagen scaffold and an disposable instrument system, which includes the arthroscopic scaffold delivery, the tendon staple and the bone staple instruments. The Rotation Medical Rotator Cuff […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
St. Jude Medical (STJ) announced FDA approval of its ILUMIEN OPTIS PCI Optimization System, and the product’s U.S. launch. The device gives physicians a real-time, 360-degree panoramic view of the arteries, to help with stent placement and to guide treatment for patients with coronary artery disease. But what’s the true value proposition between this new […]
On Wednesday, St. Jude Medical CEO Dan Starks fielded a couple of questions related to its Durata ICD lead on its fourth-quarter earnings call, although there were none on a possible recall of the product, despite my expectations. The Durata ICD lead has been troubled by its association with a recalled, previous-generation ICD lead and […]
The shoe finally dropped. The U.S. Food and Drug Administration sent a warning letter to St. Jude Medical (NYSE:STJ) on Jan. 10 regarding its inadequate design validation process for the Durata ICD lead at the medical device firm’s Sylmar, California manufacturing plant. The warning letter was expected as the company’s CEO Dan Starks had already […]
What do you do when the biggest market you play in continues to be weak, hospitals are buying less of your products, Europe, which used to be reliable, is now hobbled under austerity measures, and clinical trials don’t reach end points? You lay off workers, and a few months later you cut some more. That […]
October has not been kind to St. Jude Medical (NYSE:STJ). On Wednesday, the company, apparently against all industry precedent, warned Wall Street of a possible warning letter from the U.S. Food and Drug Administration and saw its shares decline 6 percent. But earlier in October, it received communication from a key supplier that may have […]
